Literature DB >> 33584311

The Old and New Visions of Biased Agonism Through the Prism of Adenosine Receptor Signaling and Receptor/Receptor and Receptor/Protein Interactions.

Rafael Franco1,2, Rafael Rivas-Santisteban1,2, Irene Reyes-Resina3, Gemma Navarro2,4.   

Abstract

Biased signaling is a concept that has arisen in the G protein-coupled receptor (GCPR) research field, and holds promise for the development of new drug development strategies. It consists of different signaling outputs depending on the agonist's chemical structure. Here we review the most accepted mechanisms for explaining biased agonism, namely the induced fit hypothesis and the key/lock hypothesis, but we also consider how bias can be produced by a given agonist. In fact, different signaling outputs may originate at a given receptor when activated by, for instance, the endogenous agonist. We take advantage of results obtained with adenosine receptors to explain how such mechanism of functional selectivity depends on the context, being receptor-receptor interactions (heteromerization) one of the most relevant and most studied mechanisms for mammalian homeostasis. Considering all the possible mechanisms underlying functional selectivity is essential to optimize the selection of biased agonists in the design of drugs targeting GPCRs.
Copyright © 2021 Franco, Rivas-Santisteban, Reyes-Resina and Navarro.

Entities:  

Keywords:  GPCR; MAPK pathway; adenylyl cyclase; cAMP; heteromer; receptor-receptor interactions, functional selectivity; tetramer

Year:  2021        PMID: 33584311      PMCID: PMC7878529          DOI: 10.3389/fphar.2020.628601

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  43 in total

1.  Functional selectivity and biased receptor signaling.

Authors:  Terry Kenakin
Journal:  J Pharmacol Exp Ther       Date:  2010-10-28       Impact factor: 4.030

Review 2.  Functional selectivity and classical concepts of quantitative pharmacology.

Authors:  Jonathan D Urban; William P Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; Harel Weinstein; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2006-06-27       Impact factor: 4.030

3.  Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers.

Authors:  Francisco Ciruela; Vicent Casadó; Ricardo J Rodrigues; Rafael Luján; Javier Burgueño; Meritxell Canals; Janusz Borycz; Nelson Rebola; Steven R Goldberg; Josefa Mallol; Antonio Cortés; Enric I Canela; Juan F López-Giménez; Graeme Milligan; Carme Lluis; Rodrigo A Cunha; Sergi Ferré; Rafael Franco
Journal:  J Neurosci       Date:  2006-02-15       Impact factor: 6.167

4.  A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.

Authors:  Tomoyoshi Kondo; Yoshikuni Mizuno
Journal:  Clin Neuropharmacol       Date:  2015 Mar-Apr       Impact factor: 1.592

5.  Biased agonism.

Authors:  Terry Kenakin
Journal:  F1000 Biol Rep       Date:  2009-11-26

6.  Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors.

Authors:  Sonja Hinz; Gemma Navarro; Dasiel Borroto-Escuela; Benjamin F Seibt; York-Christoph Ammon; Elisabetta de Filippo; Azeem Danish; Svenja K Lacher; Barbora Červinková; Muhammad Rafehi; Kjell Fuxe; Anke C Schiedel; Rafael Franco; Christa E Müller
Journal:  Oncotarget       Date:  2018-02-06

7.  Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.

Authors:  Yoshikuni Mizuno; Tomoyoshi Kondo
Journal:  Mov Disord       Date:  2013-03-11       Impact factor: 10.338

8.  Quaternary structure of a G-protein-coupled receptor heterotetramer in complex with Gi and Gs.

Authors:  Gemma Navarro; Arnau Cordomí; Monika Zelman-Femiak; Marc Brugarolas; Estefania Moreno; David Aguinaga; Laura Perez-Benito; Antoni Cortés; Vicent Casadó; Josefa Mallol; Enric I Canela; Carme Lluís; Leonardo Pardo; Ana J García-Sáez; Peter J McCormick; Rafael Franco
Journal:  BMC Biol       Date:  2016-04-05       Impact factor: 7.431

9.  Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation.

Authors:  Alberto J Rico; Iria G Dopeso-Reyes; Eva Martínez-Pinilla; Diego Sucunza; Diego Pignataro; Elvira Roda; David Marín-Ramos; José L Labandeira-García; Susan R George; Rafael Franco; José L Lanciego
Journal:  Brain Struct Funct       Date:  2016-09-09       Impact factor: 3.270

View more
  6 in total

1.  Expression of the Adenosine A2A-A3 Receptor Heteromer in Different Brain Regions and Marked Upregulation in the Microglia of the Transgenic APPSw,Ind Alzheimer's Disease Model.

Authors:  Alejandro Lillo; Iu Raïch; Jaume Lillo; Catalina Pérez-Olives; Gemma Navarro; Rafael Franco
Journal:  Biomedicines       Date:  2022-01-19

Review 2.  The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors.

Authors:  Rafael Franco; Paula Morales; Gemma Navarro; Nadine Jagerovic; Irene Reyes-Resina
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

Review 3.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

4.  Control of Directed Cell Migration after Tubular Cell Injury by Nucleotide Signaling.

Authors:  Sabrina Gessler; Clara Guthmann; Vera Schuler; Miriam Lilienkamp; Gerd Walz; Toma Antonov Yakulov
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

Review 5.  Adenosine A2A Receptors as Biomarkers of Brain Diseases.

Authors:  Ana Moreira-de-Sá; Vanessa S Lourenço; Paula M Canas; Rodrigo A Cunha
Journal:  Front Neurosci       Date:  2021-07-16       Impact factor: 4.677

6.  Molecular Integration in Adenosine Heteroreceptor Complexes Through Allosteric and De-Phosphorylation (STEP) Mechanisms and its Role in Brain Disease.

Authors:  Dasiel O Borroto-Escuela; Luca Ferraro; Kjell Fuxe
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.